Dr. Bristow
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update
August 05, 2020 16:15 ET | ARCA biopharma, Inc.
AB201 being developed as a potential treatment for COVID-19 and other RNA virus associated diseasesARCA anticipates filing an IND for AB201 in Q3 2020 and initiating Phase 2 clinical testing in Q4...
Dr. Bristow
ARCA biopharma Announces AB201 Development Program for Treatment of COVID-19 Associated Coagulopathy
May 28, 2020 08:00 ET | ARCA biopharma, Inc.
AB201 (rNAPc2) is being developed as a potential treatment for COVID Associated Coagulopathy, a condition characterized by abnormal blood clotting in patients with COVID-19Previous safety data in more...
U.S. FDA Approves Te
U.S. FDA Approves Terumo BCT’s Sodium Citrate 4% w/v Anticoagulant Solution Amid Shortage
July 18, 2018 10:04 ET | Terumo BCT
Lakewood, Colorado, USA, July 18, 2018 (GLOBE NEWSWIRE) -- The U.S. Food and Drug Administration (FDA) recently approved Terumo BCT’s Sodium Citrate 4% w/v Anticoagulant Solution USP, indicated for...